Rezolute's Stock Plummets 90% After Ersodetug Phase 3 Trial Failure Sparks Investigation

Rezolute Faces Scrutiny Following Phase 3 Trial Failure of Ersodetug

Rezolute, Inc. encounters significant challenges as its anticipated drug, ersodetug (erso), fails to demonstrate efficacy in a critical Phase 3 clinical trial. Initially heralded as a potential breakthrough treatment for hypoglycemia stemming from hyperinsulinism (HI), the recent results from the sunRIZE trial reveal a stark contrast to earlier optimistic projections. The company previously claimed that erso could markedly reduce hypoglycemic events and enhance patient quality of life. However, the trial results indicate that the drug did not meet its primary endpoint, showing no statistically significant decrease in hypoglycemia events relative to a placebo group. Additionally, a secondary endpoint measuring daily hypoglycemia time through continuous glucose monitoring also fell short of expectations.

The fallout from these disappointing results is immediate and severe. Investors react sharply, with Rezolute's share price plummeting by as much as 90% during intraday trading on December 11, 2025. The abrupt decline prompts analysts to reevaluate their positions, leading to a downgrade of the company's rating from "outperform" to "neutral," alongside a drastic reduction of the price target from $12 to $1. This swift market reaction underscores the heightened volatility and risk associated with pharmaceutical investments, particularly when clinical trials yield unfavorable outcomes.

In light of these developments, the national shareholder rights law firm Hagens Berman initiates an investigation into Rezolute. The firm aims to determine whether the company misled investors regarding ersodetug's effectiveness and its potential in the market. Reed Kathrein, a partner at Hagens Berman, highlights the investigation's focus on the accuracy of Rezolute's prior communications about the drug and its commercial viability. Affected investors are encouraged to report their losses and share any relevant information to assist in the inquiry.

The implications of this trial failure extend beyond immediate financial repercussions for Rezolute. As the pharmaceutical industry places substantial emphasis on clinical trial outcomes, the company's reputation and future drug development efforts may be significantly impacted. The scrutiny from both investors and regulatory bodies may lead to increased challenges in securing funding and support for ongoing research initiatives. Consequently, Rezolute's management will need to navigate these turbulent waters carefully to restore confidence among stakeholders and chart a path forward in the highly competitive biopharmaceutical landscape.